
IRLAB Therapeutics Investor Relations Material
IRLAB Therapeutics AB is a research and development company developing drugs for the treatment of Parkinson's disease. IRLAB develops drugs that can stop or slow down the loss of neurons in the substantia nigra, where dopamine is produced. In Parkinson's disease, loss of these neurons leads to a gradual degeneration of the motor functions. These drugs will improve symptoms without dramatically increasing the risk of side effects
Upcoming events for
Q2 20222022-08-24
Latest company events
Ticker symbol
IRLAB
Country
Sweden